Vetinnova
PORTAL DE REFERENCIA SOBRE I+D+i
EN SANIDAD ANIMAL
 

Área Personal

Acceso al área privada de la web
Búsqueda de texto en la web

fbus

CREA TU PERFIL Grupo de Investigación
Grupo de Investigación
CREA TU PERFIL Empresa
Empresa

 Superior Th1 polarizing adjuvant

Potent alfa galactosyl ceramide analogues targeting invariant natural killer T-cells (iNKT) for selective boosting of cellular immunity. Best-in-class when benchmarked to other Th1-skewing Galcer analogues (IL-12/IFNg/IL-4 profiles). Less IL-4 production compared to aGalCer. No acute toxicity. Druggable profile and optimized for easy synthesis. Proof of concept Enhanced primary and boosted CD8+ Tcell responses in immunised mice.

· Socio buscado PartneringWe are actively seeking partners to develop or co-develop the Ghent University GalCer molecules to applications in the vaccine and/or oncology field.

Novel class of superior Th1 polarizing glycolipids valuable as vaccine adjuvant or adjuvant therapy in oncology.

Sven Arnouts
sven.arnouts@ugent.be
+32 495 707 334

Destacados pie

Vetdivulga
Una iniciativa de

Vet + i